- While the interim data looks fantastic, and some are pushing for early approval of the drug by the FDA, some questions remain surrounding the academic integrity of the work.
- Another Journal has come forward with results of an investigation and review of foundational papers key to Cassava's current drug for Alzheimer's Disease.
- Regardless of where you fall on this argument, this is a blow to the short theses that have been published.
- All things considered, all that matters is the data and the drug will either be shown to be truly effective in the phase 3 trials, or it will not.
For further details see:
Cassava Sciences Stock: Here We Go Again